| Autor: |
Lu, Zhou, Lin, Michael, Downe, Paul, Chong, Shanley, Ling, Silvia |
| Zdroj: |
Annals of Nuclear Medicine; Oct2014, Vol. 28 Issue 8, p805-811, 7p |
| Abstrakt: |
Background: [(18)F]fluorodeoxyglucose positron emission tomography (PET) is a useful staging investigation for follicular lymphoma (FL). Recent studies have shown that positive post-treatment PET is also a strong predictor of inferior overall survival. Purpose: To evaluate the predictive value of mid- and post-treatment PET in FL patients with respect to progression-free survival (PFS) and overall survival (OS). Methods: We included 57 patients with indolent FL (grade 1, 2, and 3a) who received induction chemotherapy. Mid- and post-treatment PET results were correlated with PFS and OS retrospectively and analysed using Kaplan-Meier survival analysis and Cox regression. Results: Post-treatment PET was predictive of OS (mean OS 95.2 vs. 45.0 months for PET-negative vs. PET-positive, p < 0.001) and showed a trend towards significance for PFS (mean PFS 74.4 vs. 38.2 months for PET- vs. PET+, p = 0.083). 3-year PFS for post-treatment PET- and PET+ patients were 72 and 30 %, respectively. 3-year OS were 96 and 60 %, respectively. Mid-treatment PET was not predictive of PFS (mean PFS 78.5 vs. 51.0 months for PET- vs. PET+, p = 0.35) nor OS (mean OS 89.9 vs. 76.6 months for PET- vs. PET+, p = 0.92). Conclusion: Post-treatment PET is predictive of OS in indolent FL. It identifies patients who might benefit from more intensive follow-up, enrolment in clinical trials or second-line therapy. Mid-treatment PET scan results did not appear to predict long-term treatment outcomes. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Full text from SpringerLink